Table 2.
Laboratory findings of six kidney transplant recipients with COVID-19 on admission
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | |
|---|---|---|---|---|---|---|
| WBC (× 109/L) (4–10.5) | 5.1 | 3.7 | 10.3 | 3.7 | 2 | 5.3 |
| Lymphocyte (× 109/L) (1–3.5) | 0.82 | 0.41 | 0.31 | 0.41 | 0.12 | 0.3 |
| Hb(g/dL) (13–17.5) | 12.1 | 10.6 | 11.2 | 9.6 | 5.1 | 8 |
| Platelets (× 109/L) (150–400) | 172 | 199 | 253 | 175 | 125 | 381 |
| Baseline Cr(mg/dL) (0.7–1.4) | 1.4 | 1.48 | 1.47 | 1.45 | 2.46 | 2.5 |
| Admission Cr(mg/dL) (0.7–1.4) | 2 | 2.2 | 3.5 | 2.4 | 3.8 | 3.5 |
| Baseline eGFR(mL/min/1.73m2) (> 90) | 59 | 52 | 41 | 40 | 22 | 15 |
| Urea (mg/dL) (18–55) | 46 | 49 | 91 | 213 | 126 | 120 |
| ESR (mm) (< 18) | 28 | 56 | 86 | 96 | 46 | 110 |
| CRP (mg/L) (< 6) | 14.8 | 99.2 | 154 | 83 | 147 | 150 |
| Procalcitonin(ng/mL) (< 0.36) | 0.55 | 0.2 | 0.33 | 0.45 | – | 0.72 |
| Ferritin (ng/mL) (21.3–274.7) | > 2000 | 1598 | 962.7 | 425 | > 2000 | > 2000 |
| LDH (U/L) (< 480) | 1230 | 572 | 733 | 770 | 476 | 978 |
| First-Troponin (ng/mL) (< 26) | 193.6 | 6.1 | – | 33.7 | 233.7 | 49.4 |
| D-dimer (ng/mL) (< 250) | 1310.1 | – | 1162.7 | 971.7 | 472.4 | > 10,000 |
| AST (U/L) (< 38) | 67 | 83 | 37 | 36 | 45 | 61 |
| ALT (U/L) (< 41) | 48 | 60 | 32 | 19 | 34 | 35 |
| ALP (U/L) (< 270) | 158 | 110 | 173 | 120 | 90 | 200 |
| Albumin (gr/dL) (3.5–5.2) | 3.2 | 3.5 | 2.7 | 3.4 | 4.4 | – |
| Urine proteina | 3 + | 1 + | Trace | 2 + | Negative | Trace |
ALP alkaline phosphatase, ALT alanine transaminase, AST aspartate aminotransferase, COVID-19 coronavirus disease 2019, Cr creatinine, CRP C-reactive protein, eGFR estimated glomerular filtration rate, ESR erythrocyte sedimentation rate, Hb hemoglobin, LDH lactate dehydrogenase, WBC white blood cells
aUrine protein is described as: negative, 0 mg/dL; trace, 15–30 mg/dL; 1 + , 30–100 mg/dL; 2 + , 100–300 mg/dL; 3 + , 300–1000 mg/dL; 4 + , more than 1000 mg/dL